stockrow10x Genomics
TXG Healthcare Medical Devices
10x Genomics' revenue for fiscal 2025 (year ended December 2025) was $642.8 million, up 5.25% from fiscal 2024.
- Revenue
- +1.12%
- EPS
- +31.8%
- Free cash flow
- −4.61%
Quarter to September 2026, against a year earlier
Follow TXG
Alert me
10x Genomics (TXG) EBITDA
10x Genomics's EBITDA for fiscal 2025 was −$17.2M, compared with −$150.9M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$40.4M. Over the past ten years it has ranged from −$515.1M (fiscal 2020) to −$14.1M (fiscal 2017); the current reading is higher than 89% of that period. 10x Genomics ranks 120th of 147 Medical Devices companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$17.2M | — |
| FY2024 | −$150.9M | — |
| FY2023 | −$221.7M | — |
| FY2022 | −$134.9M | — |
| FY2021 | −$24.0M | — |
| FY2020 | −$515.1M | — |
| FY2019 | −$23.5M | — |
| FY2018 | −$106.9M | — |
| FY2017 | −$14.1M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$5.9M | — |
| Mar 2026 | −$7.1M | — |
| Dec 2025 | −$8.3M | — |
| Sep 2025 | −$19.2M | — |
| 26 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | $2.6B |
| GMED Globus Medical, Inc. compare | $932.9M |
| PODD Insulet Corporation compare | $693.3M |
| HAE Haemonetics Corporation compare | $273.8M |
| PEN Penumbra, Inc. compare | $209.4M |
| BRKR Bruker Corporation compare | $158.7M |
| TXG 10x Genomics | −$40.4M |
| BIO.B Bio-Rad Laboratories, Inc. compare | −$61.9M |
| BIO Bio-Rad Laboratories, Inc. compare | −$61.9M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on TXG
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement